Alto Neuroscience ANRO
NYSE ANRO
$24.81 -0.51 (-2.01%)
At close: Oct 2, 2026 · 4:00 PM EDT

Alto Neuroscience (ANRO) Gains from Sales and Divestitures (2023 - 2026)

Updated

Alto Neuroscience (ANRO) posted Gains from Sales and Divestitures of -$9,000 for Q1 2026, compared with -$41,000 a year earlier.

Analysis

Alto Neuroscience (ANRO) Gains from Sales and Divestitures (2023 - 2026) Analysis & Trends

For FY2025, Alto Neuroscience's Gains from Sales and Divestitures came in at -$156,000.

  • In prior years, Alto Neuroscience's Gains from Sales and Divestitures was -$52,000 in FY2024 and -$140,000 in FY2023.
  • Quarterly Gains from Sales and Divestitures has run from a low of -$120,000 in Q4 2023 to a high of -$1,000 in Q2 2025 over five years.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn
10 Alto Neuroscience 870.68 Mn 870.68 Mn -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2026 -9,000.00
Sep 30, 2025 -114,000.00
Jun 30, 2025 -1,000.00
Mar 31, 2025 -41,000.00
Dec 31, 2024 -30,000.00
Sep 30, 2024 -4,000.00
Jun 30, 2024 -18,000.00
Dec 31, 2023 -120,000.00
API Access

Alto Neuroscience Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=ANRO&period=max&api_key=YOUR_API_KEY